What is the primary purpose of this 10-Q filing for Bristol Myers Squibb?

The primary purpose of this 10-Q filing is to provide investors and the public with a concise update on Bristol Myers Squibb's financial performance and operational status for the quarterly period ending June 29, 1995. It allows stakeholders to track the company's progress and make informed investment decisions.

Where can I find the detailed financial statements and management discussion from this report?

The provided text is a directory listing from the SEC's EDGAR database. To access the detailed financial statements, management's discussion and analysis, and other narrative sections of the 10-Q filing, you would need to navigate to the full report document within the EDGAR system, typically in .txt or HTML format.

What key financial metrics should I look for in this report to understand BMY's performance?

When reviewing the full 10-Q report, investors should focus on key metrics such as revenue growth, net income, earnings per share (EPS), operating expenses, cash flow from operations, and any significant changes in the company's balance sheet. Comparing these figures to previous periods and industry benchmarks can provide valuable insights into the company's performance and trends.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY1995

Summary

Bristol Myers Squibb Co. (BMY) filed its quarterly report for the period ending June 29, 1995. This filing provides a snapshot of the company's financial performance and operational status during the second quarter of 1995. Investors should note any significant changes in revenue, earnings, and overall financial health as detailed within the full report, though specific financial figures are not present in the provided text. The filing is part of the company's ongoing commitment to transparent disclosure to the investing public, allowing stakeholders to assess the company's trajectory and make informed investment decisions.

Key Highlights

1Bristol Myers Squibb Co. (BMY) filed its 10-Q quarterly report for the period ending June 29, 1995.
2The report was filed with the SEC on August 13, 1995, indicating timely disclosure.
3This filing provides crucial information for investors regarding the company's financial performance during the second quarter of 1995.
4The report is part of the EDGAR database, accessible for public review.
5Investors can use this filing to assess the company's operational and financial standing during the specified period.
6The filing signifies Bristol Myers Squibb's commitment to regulatory compliance and investor relations.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 1995

Summary

Key Highlights

Frequently Asked Questions